The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Open accessAbstract
BACKGROUND: The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures. METHODS: We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. RESULTS: Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan-Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. CONCLUSIONS: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
Schena, M., Shalon, D., Davis, R. W., & Brown, P. O. (1995) · Science · doi:10.1126/science.270.5235.467 · Cited by 9,609
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Self-citationBrown, A. S., Brummel‐Smith, K., Burgess, L., D'Agostino, R. B., Goldschmidt, J. W., Halter, J. B., Hazzard, W. R., Jahnigen, D. W., Phelps, C., Raskind, M., et al. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb02362.x · Cited by 1,331
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Cited by
Items 201–300 of 328
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Dubsky, P., Brase, J. C., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.671 · Cited by 350
Mantovani, A., Sica, A., Allavena, P., Garlanda, C., & Locati, M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.02.008 · Cited by 350
Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer
Cho, J. Y., Lim, J. Y., Cheong, J. H., Park, Y.-Y., Yoon, S.-L., Kim, S. M., Kim, S.-B., Kim, H., Hong, S. W., Park, Y. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2180 · Cited by 349
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Kao, K.-J., Chang, K.-M., Hsu, H.-C., & Huang, A. T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-143 · Cited by 348
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201506312 · Cited by 344
Cronin, M., Sangli, C., Liu, M.-L., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Langone, K. C., & Watson, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076497 · Cited by 343
Self-citationTravis, L. B., Rabkin, C. S., Brown, L. M., Allan, J. M., Alter, B. P., Ambrosone, C. B., Begg, C. B., Caporaso, N., Chanock, S., DeMichele, A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj001 · Cited by 342
Knezevic, D., Goddard, A. D., Natraj, N., Cherbavaz, D. B., Clark-Langone, K. M., Snable, J., Watson, D., Falzarano, S. M., Magi-Galluzzi, C., Klein, E. A., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-690 · Cited by 339
Self-citationA clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021: Featured Updates to the NCCN Guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0023 · Cited by 337
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Bastien, R. R., Rodríguez-Lescure, Á., Ebbert, M. T., Prat, A., Munárriz, B., Rowe, L., Miller, P., Ruiz-Borrego, M., Anderson, D., Lyons, B., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-44 · Cited by 334
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Self-citationParise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Brannon, A. R., Reddy, A., Seiler, M., Arreola, A., Moore, D. T., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Liu, H., Nathanson, K. L., et al. (2010) · Genes & Cancer · doi:10.1177/1947601909359929 · Cited by 331
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Fasching, P. A., Heusinger, K., Haeberle, L., Niklos, M., Hein, A., Bayer, C. M., Rauh, C., Schulz-Wendtland, R., Bani, M. R., Schrauder, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-486 · Cited by 328
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Chang, E. C., Frasor, J., Komm, B., & Katzenellenbogen, B. S. (2006) · Endocrinology · doi:10.1210/en.2006-0563 · Cited by 325
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Hamam, R., Hamam, D., Alsaleh, K. A., Kassem, M., Zaher, W., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.440 · Cited by 322
Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging
Rutman, A. M., & Kuo, M. D. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.01.050 · Cited by 321
Novel patterns of genome rearrangement and their association with survival in breast cancer
Hicks, J., Krasnitz, A., Lakshmi, B., Navin, N. E., Riggs, M., Leibu, E., Esposito, D., Alexander, J., Troge, J., Grubor, V., et al. (2006) · Genome Research · doi:10.1101/gr.5460106 · Cited by 319
Sestak, I., Buus, R., Cuzick, J., Dubsky, P., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D., Schnabel, C., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 318
Self-citationDawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Ki-67 as a prognostic marker according to breast cancer molecular subtype
Nahed, A. S., & Shaimaa, M. Y. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0066 · Cited by 317
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
Local Therapy and Survival in Breast Cancer
Punglia, R. S., Morrow, M., Winer, E. P., & Harris, J. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065241 · Cited by 317
Lee, J. K., Havaleshko, D. M., Cho, H., Weinstein, J. N., Kaldjian, E. P., Karpovich, J., Grimshaw, A., & Theodorescu, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610292104 · Cited by 316
Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5026 · Cited by 315
Millar, E. K. A., Graham, P. H., O'Toole, S. A., McNeil, C. M., Browne, L., Morey, A. L., Eggleton, S., Beretov, J., Theocharous, C., Capp, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7075 · Cited by 314
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A. C., Bontempi, G., Quackenbush, J., & Sotiriou, C. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr545 · Cited by 313
Inflammation by remote control
Mantovani, A. (2005) · Nature · doi:10.1038/435752a · Cited by 313
Asplund, A., Edqvist, P. D., Schwenk, J. M., & Pontén, F. (2012) · PROTEOMICS · doi:10.1002/pmic.201100504 · Cited by 312
Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., & Storhoff, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-177 · Cited by 311
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Visceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
A new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 306
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Lo, S. S., Mumby, P. B., Norton, J., Rychlik, K., Smerage, J., Kash, J., Chew, H. K., Gaynor, E. R., Hayes, D. F., Epstein, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2119 · Cited by 303
Chia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., Mardis, E., Leung, S., Ung, K., Pritchard, K. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0286 · Cited by 302
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
Hollestelle, A., Nagel, J. H. A., Smid, M., Lam, S., Elstrodt, F., Wasielewski, M., Ng, S. S., French, P. J., Peeters, J. K., Rozendaal, M. J., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0460-8 · Cited by 301
FOXP3 Expression and Overall Survival in Breast Cancer
Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Mènard, S., Tagliabue, E., & Balsari, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9036 · Cited by 301
O'Connell, M. J., Lavery, I., Yothers, G., Paik, S., Clark-Langone, K. M., Lopatin, M., Watson, D., Baehner, F. L., Shak, S., Baker, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9538 · Cited by 299
Self-citationGenomics and the Continuum of Cancer Care
McDermott, U., Downing, J. R., & Stratton, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0907178 · Cited by 299
Hunter, K. W., Crawford, N. P., & Alsarraj, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1988 · Cited by 298
Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018) · Translational Research · doi:10.1016/j.trsl.2017.10.010 · Cited by 295
Practical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen-Dale, A.-L., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291
A gene expression signature identifies two prognostic subgroups of basal breast cancer
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.-M., Jacquemier, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0897-9 · Cited by 290
mRNA transcript quantification in archival samples using multiplexed, color-coded probes
Reis, P. P., Waldron, L., Goswami, R. S., Xu, W., Xuan, Y., Perez-Ordonez, B., Gullane, P., Irish, J., Jurisica, I., & Kamel-Reid, S. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-46 · Cited by 283
Patient-derived xenograft models of breast cancer and their predictive power
Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0523-1 · Cited by 282
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
Sierra, J. R., Corso, S., Caione, L., Cepero, V., Conrotto, P., Cignetti, A., Piacibello, W., Kumanogoh, A., Kikutani, H., Comoglio, P. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072602 · Cited by 281
Hewitt, S. M., Lewis, F. A., Cao, Y., Conrad, R. C., Cronin, M., Danenberg, K. D., Goralski, T. J., Langmore, J. P., Raja, R. G., Williams, P. M., et al. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/132.12.1929 · Cited by 281
Self-citationAhn, S. H., Son, B. H., Kim, S. W., Kim, S. I., Jeong, J., Ko, S.-S., & Han, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3754 · Cited by 279
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Duffy, M. J. (2013) · Medical Principles and Practice · doi:10.1159/000338393 · Cited by 278
Gerami, P., Cook, R. W., Wilkinson, J., Russell, M. C., Dhillon, N., Amaria, R. N., Gonzalez, R., Lyle, S., Johnson, C. E., Oelschlager, K. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3316 · Cited by 278
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer
Hu, X., Macdonald, D. M., Huettner, P. C., Feng, Z., El Naqa, I. M., Schwarz, J. K., Mutch, D. G., Grigsby, P. W., Powell, S. N., & Wang, X. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.022 · Cited by 275
Bueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
Ahmed, S., Berzon, R. A., Revicki, D. A., Lenderking, W. R., Moinpour, C. M., Basch, E., Reeve, B. B., & Wu, A. W. (2012) · Medical Care · doi:10.1097/mlr.0b013e318268aaff · Cited by 272
Jang, J.-Y., Lee, J.-K., Jeon, Y.-K., & Kim, C.-W. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-421 · Cited by 270
Self-citationCancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Tumour-infiltrating macrophages and clinical outcome in breast cancer
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200355 · Cited by 268
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
Dowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang, F., Turcan, S., Rimner, A., Kaufman, A., Giri, D., Morris, L. G. T., Shen, R., Seshan, V., Mo, Q., Heguy, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001875 · Cited by 267
MicroRNA-301 Mediates Proliferation and Invasion in Human Breast Cancer
Shi, W., Gerster, K., Alajez, N. M., Tsang, J., Waldron, L., Pintilie, M., Hui, A. B., Sykes, J., P'ng, C., Miller, N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3369 · Cited by 266
Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
Ransohoff, D. F. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji054 · Cited by 264
Genetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
Sparano, J. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.051 · Cited by 262
Meyer, J. S., Alvarez, C., Milikowski, C., Olson, N., Russo, I., Russo, J., Glass, A., Zehnbauer, B. A., Lister, K., & Parwaresch, R. (2005) · Modern Pathology · doi:10.1038/modpathol.3800388 · Cited by 262
Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2795 · Cited by 262
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0248 · Cited by 259
Implementing a Survivorship Care Plan for Patients With Breast Cancer
Ganz, P. A., & Hahn, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2851 · Cited by 259
Long term side effects of adjuvant chemotherapy in patients with early breast cancer
Tao, J. J., Visvanathan, K., & Wolff, A. C. (2015) · The Breast · doi:10.1016/j.breast.2015.07.035 · Cited by 258
Identification of high-quality cancer prognostic markers and metastasis network modules
Li, J., Lenferink, A. E. G., Deng, Y., Collins, C., Cui, Q., Purisima, E. O., O'Connor-McCourt, M. D., & Wang, E. (2010) · Nature Communications · doi:10.1038/ncomms1033 · Cited by 258
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Multigene prognostic tests in breast cancer: past, present, future
Győrffy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B., & Pusztai, L. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0514-2 · Cited by 257
A gene-expression signature to predict survival in breast cancer across independent data sets
Naderi, A., Teschendorff, A. E., Barbosa-Morais, N. L., Pinder, S. E., Green, A. R., Powe, D. G., Robertson, J. F. R., Aparicio, S., Ellis, I. O., Brenton, J. D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1209920 · Cited by 256
US Biomedical Research: Basic, Translational, and Clinical Sciences
Zerhouni, E. A. (2005) · JAMA · doi:10.1001/jama.294.11.1352 · Cited by 256
Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0131-9 · Cited by 255
Three-gene prognostic classifier for early-stage non small-cell lung cancer
Lau, S. K., Boutros, P. C., Pintilie, M., Blackhall, F. H., Zhu, C.-Q., Strumpf, D., Johnston, M. R., Darling, G., Keshavjee, S., Waddell, T. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0352 · Cited by 255
Herschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Luminal A Breast Cancer and Molecular Assays: A Review
Gao, J. J., & Swain, S. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0535 · Cited by 254
Rini, B., Goddard, A., Knezevic, D., Maddala, T., Zhou, M., Aydin, H., Campbell, S., Elson, P., Koscielny, S., Lopatin, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70167-1 · Cited by 254
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
Ma, X.-J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., & Erlander, M. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6944 · Cited by 252
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Tian, Q., Price, N. D., & Hood, L. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02498.x · Cited by 224
Peng, J., Zhu, J., Bergamaschi, A., Han, W., Noh, D.-Y., Pollack, J. R., & Wang, P. (2010) · The Annals of Applied Statistics · doi:10.1214/09-aoas271 · Cited by 211
Improved breast cancer histological grading using deep learning
Wang, Y., Acs, B., Robertson, S., Liu, B., Solorzano, L., Wählby, C., Hartman, J., & Rantalainen, M. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.007 · Cited by 211
Metadata
- Authors
- Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., & Wolmark, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-30
- Volume
- 351
- Issue
- 27
- Pages
- 2817-2826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105882193
- Cited by
- 6,277
- References
- 28
- FWCI
- 85.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.